A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-08. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
== Publications == The exile organization maintained a publication apparatus through the Bulletin of the Information Bureau of the People's Union for the Defense of the Motherland and Freedom, which circulated reports, political materials, and organizational information among émigré and underground anti-Bolshevik circles.
== Culture == The Cater Museum is a local history museum and charity containing artefacts recording the lives of people in the area. It is housed in an 18th and 19th-century Grade II listed building on the High Street. The Billericay Community Archive posts photos, memories and history relating to the town and surrounding areas on their website. In 2015, the Billericay Community Cinema was established; within a year, the not-for-profit and volunteer-based group won a national award: the Best New Film Society at the All Community Cinema Awards. In September 2025, it celebrated its tenth anniversary and won Cinema for All's national Community Award, which recognises outstanding community connection and involvement over the past year; its founder, Adam Adshead, also took home the Outstanding Contribution by an Individual award.
Oltipraz has been shown to suppress tumor formation in multiple rodent tissues, including the bladder, colon, liver, lung, and pancreas, by upregulating NRF2-dependent detoxification pathways. However, clinical trials of oltipraz have failed to demonstrate clear therapeutic benefit and have reported significant toxicities, including neurotoxicity and gastrointestinal disturbances. Additionally, oltipraz has been found to generate superoxide radicals, which may offset its NRF2-mediated protective effects. MIND4-17 is a selective NRF2 activator which is used for research into this pathway.
Sources: en.wikipedia.org
On 27 March the infantry and cavalry of the revolutionary army, for eight months active in Paris and surroundings, were finally disbanded, except their artillery. (Hanriot was denounced by the Revolutionary Tribunal as an accomplice of Hébert, but seems to have been protected by Robespierre.)
== Capsaicinoids == The most commonly occurring capsaicinoids are capsaicin (69%), dihydrocapsaicin (22%), nordihydrocapsaicin (7%), homocapsaicin (1%), and homodihydrocapsaicin (1%). Capsaicin and dihydrocapsaicin (both 16.0 million SHU) are the most pungent capsaicinoids. Nordihydrocapsaicin (9.1 million SHU), homocapsaicin and homodihydrocapsaicin (both 8.6 million SHU) are about half as hot. There are six natural capsaicinoids (table below). Although vanillylamide of n-nonanoic acid (Nonivamide, VNA, also PAVA) is produced synthetically for most applications, it does occur naturally in Capsicum species.
=== Weak base and weak coordinating anion === As perchloric acid is one of the strongest mineral acids, perchlorate is a very weak base in the sense of Brønsted–Lowry acid–base theory. As it is also generally a weakly coordinating anion, perchlorate is commonly used as a background, or supporting, electrolyte.
Sources: en.wikipedia.org
Glucocorticoid injections are often used for acute and localized flare-ups. About 0.1% to 0.8% of the population is affected, with onset typically occurring in young adults. While men and women are equally affected with AS, women are more likely to experience inflammation rather than fusion.
== Distribution and habitat == Psilocybe cubensis is a pan-tropical species, occurring in the Gulf Coast states and southeastern United States, Mexico, in the Central American countries of Belize, Costa Rica, Panamá, El Salvador and Guatemala, the Caribbean countries Cuba, the Dominican Republic, Puerto Rico, Guadalupe, Martinique, and Trinidad, in the South American countries of Argentina, Bolivia, Brazil, Colombia, French Guiana, Paraguay, Uruguay and Peru, Southeast Asia, including Thailand, Vietnam, Cambodia and Malaysia, India, Australia, Fiji, and possibly Nepal and Hawaii. Psilocybe cubensis is found on cow (and occasionally horse) dung, sugar cane mulch or rich pasture soil, with mushrooms appearing from February to December in the northern hemisphere, and November to April in the southern hemisphere. In Asia, the species grows on water buffalo dung. Along with other fungi that grow on cow dung, P. cubensis is thought to have colonized Australia with the introduction of cattle there, 1800 of which were on the Australian mainland by 1803—having been transported there from the Cape of Good Hope, Kolkata and the American west coast. In Australia, the species grows between northern Queensland to southern New South Wales. In March 2018, several Psilocybe cubensis specimens were collected in Zimbabwe in the Wedza District of Mashonaland East province, approx. 120 km southeast of Harare. This was the first reported occurrence of a psilocybin mushroom in Zimbabwe.
=== Human data === PFOA is resistant to degradation by natural processes such as metabolism, hydrolysis, photolysis, or biodegradation and has been found to persist in the environment. PFOA is found in environmental and biological fluids as the anion perfluorooctanoate. PFOA can be absorbed from ingestion and can penetrate skin. The acid headgroup of PFOA enables binding to proteins with fatty acid or hormone substrates such as serum albumin, liver fatty acid-binding protein, and the nuclear receptors PPARα and possibly CAR. In animals, PFOA is mainly present in the liver, blood, and kidneys. PFOA does not accumulate in fat tissue, unlike traditional organohalogen persistent organic pollutants. In humans, PFOA has an average elimination half-life of about three years. Because of this long half-life, PFOA has the potential to bioaccumulate. The levels of PFOA exposure in humans vary widely. While an average American might have 3 or 4 parts per billion of PFOA present in their blood serum, individuals occupationally exposed to PFOA have had blood serum levels over 100,000 parts per billion (100 parts per million or 0.01%) recorded. While no amount of PFOA in humans is legally recognized as harmful, DuPont was "not satisfied" with data showing their Chinese workers accumulated an average of about 2,250 parts per billion of PFOA in their blood from a starting average of around 50 parts per billion less than a year prior.
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.